The companies have expanded the scope of their strategic partnership for cytokine reduction therapy, CytoSorb, to treat patients experiencing severe whole body inflammation, Biocon Ltd said in a statement.
As part of the agreement, the Bangalore-based firm will now have the exclusive, region-wide rights to distribute CytoSorb for all critical care applications in the intensive care unit (ICU) as well as cardiac surgery applications for India and select emerging countries, it added.
"Biocon will also play a prominent leadership role in the generation of new clinical evidence to support the adoption and usage of CytoSorb," the company said.
Financial terms of the agreement were not disclosed. Biocon Marketing President Ravindra Limaye said "Our expanded partnership with CytoSorbents will now enable us to address the huge unmet needs of patients experiencing a SIRS, lung injury, liver failure, pancreatitis, post-cardiac surgery complications, and tropical diseases like malaria and dengue fever."
Severe whole body inflammation or Systemic Inflammatory Response Syndrome (SIRS), is caused by a wide range of life- -threatening conditions seen in the intensive care unit and can also be caused by surgical interventions, particularly cardiac surgery.
"We are very pleased to expand our relationship with Biocon, which has been an exceptional partner in launching CytoSorb in India," CytoSorbents Chief Executive Officer and President Phillip Chan said.
Biocon scrip closed at Rs 450.65, up 0.59 percent, on the BSE.

Latest News from Lifestyle News Desk